You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
OTOREFLECTANCE ASSESSMENT OF MIDDLE-EAR FUNCTIONING
SBC: Sonicom, Inc. Topic: N/ADESCRIPTION (provided by applicant): Otoreflectance (OR) is a new class of hearing-test instruments utilizing acoustic signals presented and recorded in the ear canal. OR instruments address the following limitations in existing instruments to screen and diagnose middle-ear function: (1) detection of otitis media, (2) prediction of conductive hearing loss, (3) detection of middle-ear dysfunction i ...
STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health -
Novel Dental Adhesives to Prevent Recurrent Caries
SBC: CuRE Innovations, LLC Topic: NIDCRDESCRIPTION provided by applicant Bacterial related marginal decay is the top reason for failure and retreatment of resin based composite restorations RBCs Retreatment of these restorations costs both the patients and insurance companies billions of dollars per year The weak point of the system is the zone known as the hybrid layer where the adhesive bonds the RBC to the dentin There are ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists
SBC: Bohemica Pharmaceuticals, LLC Topic: 100DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Novel mechanism for the treatment of epilepsy: New Vitamin K analogs target energetics and have low toxicity due to excellent specificity and low dose requirements compared to current therapies
SBC: NEUROENE THERAPEUTICS INC Topic: 106DESCRIPTION provided by applicant Epilepsy is the th most common neurological disorder with in people developing epilepsy the occurrence of more than one unprovoked seizure at some point in their lifetime Unfortunately of all patients have intractable medication resistant epilepsy Thus new anti epileptic drugs AEDs that target alternative mechanisms of action are needed ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Mutation Enriched Targeted Re Sequencing
SBC: TRANSGENOMIC, INC. Topic: 103DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Aminoglycosides with reduced ototoxicity
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Screening the Ribosome for New Target Sites
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant Nucleic acids are avenues for drug design both as therapeutics and as targets Here we propose to establish new methods for identifying antibiotic ribosome targets and lead compounds Targeting specific RNA such as rRNA which are involved in proliferation and survival of bacteria is a promising approach We are developing fast and low cost methods to screen s ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple Myeloma MM is the second most common form of blood cancer and remains an incurable and deadly disease Proteasome inhibitor PI therapy is a cornerstone in the treatment of MM but resistance to this class of agent is an emerging challenge in the clinic New therapeutic approaches that specifically target resistance are needed to maximize responses and ultimate ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis
SBC: Sanguine Diagnostics And Therapeutics, Inc. Topic: 103ABSTRACT Pancreatic cancer PC is an extremely aggressive malignancy with one of the worst prognoses of all cancers with a median survival of less than one year and an overall year survival of andlt With marked resistance to chemo and radiotherapies surgery is the only curative option In patients with localized disease and no lymph node or extra pancreatic metastases complete surgical ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of Chol-DsiRNA Polyplexes to Improve the Therapy of Breast Cancer
SBC: ACTORIUS PHARMACEUTICALS, LLC Topic: 100DESCRIPTION provided by applicant Breast cancer is the most common type of cancer in women between the ages of and and responsible for deaths annually If treated early five year survival rates for patients in the U S are between and but drop to once metastatic breast cancer has developed Thus there is a great need to develop more effective treatment strategies fo ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health